Steve Pakola - Jan 3, 2023 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Medical Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Jan 3, 2023
Transactions value $
-$111,223
Form type
4
Date filed
1/5/2023, 03:06 PM
Previous filing
Jan 4, 2022
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Tax liability -$41.7K -1.84K -10.71% $22.68 15.3K Jan 3, 2023 Direct F1
transaction RGNX Common Stock Sale -$69.6K -3.14K -20.49% $22.17 12.2K Jan 3, 2023 Direct F2, F3
transaction RGNX Common Stock Award $0 +90.6K +744.05% $0.00 103K Jan 3, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to buy) Award $0 +44.2K $0.00 44.2K Jan 3, 2023 Common Stock 44.2K $22.25 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022.
F2 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F3 This transaction was executed in multiple trades at prices ranging from $22.0000 to $22.3800. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer.
F5 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer.